Multiple functions of heterogeneous nuclear ribonucleoproteins in the positive single-stranded RNA virus life cycle
J Wang, D Sun, M Wang, A Cheng, Y Zhu… - Frontiers in …, 2022 - frontiersin.org
The heterogeneous nuclear ribonucleoproteins (hnRNPs) are a diverse family of RNA
binding proteins that are implicated in RNA metabolism, such as alternative splicing, mRNA …
binding proteins that are implicated in RNA metabolism, such as alternative splicing, mRNA …
[HTML][HTML] Hepatitis C Virus: Insights Into Its History, Treatment, Challenges, and Future Directions
LA Bernal, V Soti - Cureus, 2023 - ncbi.nlm.nih.gov
Hepatitis C virus (HCV) is a global public health concern with significant impacts. It primarily
spreads through blood-to-blood contact, such as sharing needles among drug users. Given …
spreads through blood-to-blood contact, such as sharing needles among drug users. Given …
Sustainable and equivalent improvements in symptoms and functional well‐being following viral cure from ledipasvir/sofosbuvir versus elbasvir/grazoprevir for chronic …
The PRIORITIZE trial (clinicaltrials. gov: NCT02786537) was the first comparative
effectiveness study to directly compare ledipasvir/sofosbuvir (LDV/SOF) and …
effectiveness study to directly compare ledipasvir/sofosbuvir (LDV/SOF) and …
三种DAAs 方案治疗慢性丙型肝炎患者两年随访研究
王焱， 韩军， 杨美蓉 - 实用肝脏病杂志, 2024 - manu43.magtech.com.cn
三种DAAs 方案治疗慢性丙型肝炎患者两年随访研究 Page 1 ∗ 基金项目:中国肝炎防治研究基金
会天晴肝病研究基金资助 项目(编号:TQGB20210198) 作者单位:214000 江苏省无锡市江南大学 …
会天晴肝病研究基金资助 项目(编号:TQGB20210198) 作者单位:214000 江苏省无锡市江南大学 …
Long-term Follow-up of Hepatitis C Patients Who Achieved Sustained Virologic Response in the Pragmatic PRIORITIZE Study
AS Lok, J Moon, KE Sherman, M Khalili… - Clinical …, 2023 - cghjournal.org
Multiple real-world studies have confirmed the safety and efficacy of hepatitis C (HCV)
directacting antivirals (DAAs); however, few studies have provided data on long-term …
directacting antivirals (DAAs); however, few studies have provided data on long-term …
Revolutionizing HCV Therapy: microRNA Approaches in New Era
M Shafaati, M Salehi, M Zare - Liver Cancer-Multidisciplinary …, 2024 - books.google.com
Since the development and evolution of COVID-19 immunization, the use of mRNA-based
technologies has led to revolutionary changes due to the potential of RNA-based therapies …
technologies has led to revolutionary changes due to the potential of RNA-based therapies …
Concordance between Patients and Clinicians for Reporting Symptoms Associated with Treatment for Chronic Hepatitis C during a Pragmatic Clinical Trial
BB Reeve, L Michael, JA Peter, PW Stewart… - …, 2022 - Wiley Online Library
Background. Despite high efficacy rates for direct acting antiviral regimens to cure hepatitis
C virus infection, many patients experience treatment‐related symptoms. Accurate reporting …
C virus infection, many patients experience treatment‐related symptoms. Accurate reporting …
[HTML][HTML] Revolutionizing HCV Therapy: microRNA Approaches in New Era of Treatment
M Shafaati, M Salehi, M Zare - 2024 - intechopen.com
Since the development and evolution of COVID-19 immunization, the use of mRNA-based
technologies has led to revolutionary changes due to the potential of RNA-based therapies …
technologies has led to revolutionary changes due to the potential of RNA-based therapies …
[PDF][PDF] A Ten-Year Retrospective Cohort Study of Real-World Effectiveness of Sofosbuvir-Based Regimens for Hepatitis C in a Single Center in China
Q Yang, F Xu, Y Shen, B Pi, F Lv - Infectious Microbes & Diseases, 2023 - journals.lww.com
This study aimed to review the trends of hepatitis C virus (HCV) treatment over the past
decade and to analyze the effectiveness of sofosbuvir (SOF)-based direct-acting antiviral …
decade and to analyze the effectiveness of sofosbuvir (SOF)-based direct-acting antiviral …